This CME program will highlight recent scientific advances in the treatment and management of patients with metastatic melanoma as presented at the 2017 American Academy of Dermatology Annual Meeting in Orlando, Florida. The two expert faculty will discuss the most up-to-date treatment plans and therapeutic advances for patients with metastatic melanoma. The faculty will summarize recent clinical trial data in comparison to past trial data to allow physicians to understand advances. The faculty will also discuss new and emerging combination therapies to better treat patients. Upon completion of this activity, physicians will gain better insight into new therapeutic treatment options to improve outcomes for patients with metastatic melanoma.
Dermatologists, oncologists, and other healthcare clinicians responsible for the care of patients with melanoma.
- Review tumor status, patient screening and appropriate treatment selection strategies for the treatment of metastatic melanoma.
- Examine clinical trial data of current and emerging first-line and/or combination therapies for the treatment of metastatic melanoma presented at AAD 2017.
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Jeffrey Weber, MD||Consultant/Advisor: Amgen, Inc.; Novartis|
|Mario Sznol, MD||Consultant/Advisor: Adaptimmune Therapeutics; Adaptive Biotechnologies; Agonox; Alexion Pharmaceutical Company; Amphivena Therapeutics, Inc; Arbutus Biopharma Company; AstraZeneca/Medimmune; Baxalta-Shire Company; Bristol-Myers Squibb Company; Eli and Lily Company; Genentech, Inc.; Inovio Pharmaceuticals; Intensity Therapeutics; Lion Biotechnologies Company; Lycera Corp. Company; Merck & Co. Pharmaceutical Company; Modulate; Nektar; Pfizer, Inc.; Omniox; Pieris Pharmaceuticals Biotechnology Company; Prometheus Laboratories Biotechnology Company; Seattle Genetics Biotechnology Company; Theravance Pharmaceutical Company and The Pierre Fabre Group|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski and Megan Gentile hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Incyte Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Incyte Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME Inquiries/Special Needs
Provided by AcademicCME.